Patents Assigned to ATROGI AB
  • Patent number: 11793774
    Abstract: There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R4 and n have meanings as provided in the description.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: October 24, 2023
    Assignee: ATROGI AB
    Inventors: Benjamin Pelcman, Tore Bengtsson
  • Patent number: 11648216
    Abstract: There is herein provided a compound of formula (I).
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: May 16, 2023
    Assignee: ATROGI AB
    Inventors: Benjamin Pelcman, Tore Bengtsson
  • Patent number: 11427539
    Abstract: There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R1, ring A, m and n have meanings as provided in the description.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: August 30, 2022
    Assignee: ATROGI AB
    Inventors: Benjamin Pelcman, Tore Bengtsson
  • Patent number: 11357757
    Abstract: There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the ring containing Q1 to Q5, and the groups R1, R2 and R3, have meanings as provided in the description.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: June 14, 2022
    Assignee: ATROGI AB
    Inventor: Benjamin Pelcman
  • Publication number: 20190314301
    Abstract: There is herein provided pharmaceutical formulations and kits-of-parts comprising a ?2-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, and a ?3-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof. This combination of active agents finds particular utility in the treatment of type 2 diabetes.
    Type: Application
    Filed: July 13, 2017
    Publication date: October 17, 2019
    Applicant: Atrogi AB
    Inventors: Benjamin PELCMAN, Tore BENGTSSON
  • Patent number: 10288602
    Abstract: A method of screening for a candidate compound for the treatment of a condition involving dysregulation of metabolism in a mammal, said method comprising bringing a compound into contact with at least one population of cells, comprising cells that express mTOR and Akt and that are capable of activating mTORC2 and Akt; determining mTORC2 activity and Akt activity in cells brought into contact with the compound, and identifying the candidate compound based on the determined mTORC2 activity and Akt activity. A kit for use in such a method of. A compound for use in a method of treatment of a condition involving dysregulation of metabolism in a mammal, and a method of treatment of such a condition.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: May 14, 2019
    Assignee: ATROGI AB
    Inventor: Tore Bengtsson
  • Patent number: 9891212
    Abstract: A method to identify a candidate compound for use in the treatment of a condition involving dysregulation of glucose homeostasis or of glucose uptake in a mammal, by identifying a candidate compound that causes an increase in translocation of GLUT without causing an increase in the production of cAMP. A kit for use in such a method. A method of treatment of a condition involving dysregulation of glucose homeostasis or of glucose uptake in a mammal and a compound for use in such a method.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: February 13, 2018
    Assignee: ATROGI AB
    Inventor: Tore Bengtsson
  • Patent number: 9784726
    Abstract: A method of screening for a candidate compound for the treatment of a condition involving dysregulation of metabolism in a mammal, said method comprising bringing a compound into contact with at least one population of cells, comprising cells that express mTOR and Akt and that are capable of activating mTORC2 and Akt; determining mTORC2 activity and Akt activity in cells brought into contact with the compound, and identifying the candidate compound based on the determined mTORC2 activity and Akt activity. A kit for use in such a method of. A compound for use in a method of treatment of a condition involving dysregulation of metabolism in a mammal, and a method of treatment of such a condition.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: October 10, 2017
    Assignee: ATROGI AB
    Inventor: Tore Bengtsson
  • Patent number: 9657348
    Abstract: A method of screening for a candidate compound for the treatment of a condition involving dysregulation of metabolism in a mammal, by bringing a compound into contact with cells that express a GPCR and that further express a GRK, determining whether the contacting causes a response of the GRK in cells brought into contact with the compound, determining whether the contacting causes a response of a classical secondary messenger in cells brought into contact with the compound; and identifying the candidate compound based on the determined GRK response and response of a classical secondary messenger in the cells. A kit for use in the method. A compound for use in the treatment of a condition involving dysregulation of metabolism in a mammal and a method of treatment of such a condition.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: May 23, 2017
    Assignee: ATROGI AB
    Inventor: Tore Bengtsson
  • Publication number: 20170016881
    Abstract: A method to identify a candidate compound for use in the treatment of a condition involving dysregulation of glucose homeostasis or of glucose uptake in a mammal, by identifying a candidate compound that causes an increase in translocation of GLUT without causing an increase in the production of cAMP. A kit for use in such a method. A method of treatment of a condition involving dysregulation of glucose homeostasis or of glucose uptake in a mammal and a compound for use in such a method.
    Type: Application
    Filed: December 16, 2013
    Publication date: January 19, 2017
    Applicant: ATROGI AB
    Inventor: Tore Bengtsson
  • Publication number: 20150344958
    Abstract: A method of screening for a candidate compound for the treatment of a condition involving dysregulation of metabolism in a mammal, by bringing a compound into contact with cells that express a GPCR and that further express a GRK, determining whether the contacting causes a response of the GRK in cells brought into contact with the compound, determining whether the contacting causes a response of a classical secondary messenger in cells brought into contact with the compound; and identifying the candidate compound based on the determined GRK response and response of a classical secondary messenger in the cells. A kit for use in the method. A compound for use in the treatment of a condition involving dysregulation of metabolism in a mammal and a method of treatment of such a condition.
    Type: Application
    Filed: January 13, 2014
    Publication date: December 3, 2015
    Applicant: ATROGI AB
    Inventor: Tore Bengtsson